In SF Bay area, have heard this message loud and clear in trade press.
Thanks, master. This corroborates what I posted in #msg-35247778 and is exactly what I would have expected from the biotech trade press.
Big Bio was close to losing the FoB fight about a year ago, but the deep recession in the US economy has given them the perfect cover for a brand new argument centered on jobs and tax revenues. I don’t know how this is going to play out, but it’s clear that the proponents of FoB’s have a more difficult task ahead than they bargained for.
Absent a sharp and quick recovery in the economy (possible, I suppose, but highly unlikely), Bruce Downey’s prediction of no FoB legislation in 2009 is hard to rebut.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”